Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Amgen Inc.    AMGN


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Amgen : Update Regarding COVID-19

share with twitter share with LinkedIn share with facebook
share via e-mail
03/11/2020 | 10:39pm EDT
Amgen Update Regarding COVID-19

March 11, 2020

As the COVID-19 situation evolves globally, Amgen continues to provide an uninterrupted supply of medicines for patients around the world. We have taken action to support the health and well-being of our staff members and to activate our business continuity plans.

Staff and Community

  • The health and safety of our staff members remains a top priority.
  • Globally, Amgen has suspended international business travel through April 17.
  • We have suspended attendance at medical congresses, conferences and other large events through April 17.
  • We are supporting our staff, including those who are working from home, and are leveraging virtual meeting technology.
  • We have activated our business continuity plans to avoid or minimize business disruption and ensure the well-being of our staff.
  • Enhanced cleaning procedures and visitor screening are being implemented at all Amgen locations.


  • Individuals on Amgen medicines who have questions or concerns about their treatment plan should consult with their doctors.
  • If you have additional questions or concerns, contact us at 1-800-772-6436.
  • Patients can also review COVID-19 guidance from the World Health Organization or the U.S. Centers for Disease Control.

Supply of Our Medicines

  • Amgen continues to provide an uninterrupted supply of medicines for patients around the world. Based on inventory levels, we do not anticipate a shortage of our medicines due to COVID-19 at this time.
  • We are monitoring our raw material inventory levels and taking additional measures to mitigate against interruption.

Clinical Trials

  • We have a vast amount of clinical work going on at investigational sites across the globe. We are monitoring this dynamic situation closely.

Impact to Our Business

  • Amgen continues to provide an uninterrupted supply of medicines for patients around the world.
  • We don't know the extent to which COVID-19 (coronavirus) will continue to spread and impact society.
  • At this stage, we cannot rule out future impact on our business including sales, manufacturing and clinical trials.


Amgen Inc. published this content on 11 March 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 March 2020 03:38:03 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on AMGEN INC.
05/20AMGEN : Science, Execution, and COVID-19 Response Highlighted at Annual Stockhol..
05/20AMGEN : Announces Voting Results Of Annual Meeting Of Stockholders
05/20AMGEN INC : Submission of Matters to a Vote of Security Holders (form 8-K)
05/20AMGEN : Investor Insights Newsletter Q1 2020
05/19AMGEN : Q4 2019 Financial Results
05/15AMGEN INC. : Ex-dividend day for
05/13AMGEN : Dancing and Kickboxing to Stay Fit Between Conference Calls
05/13AMGEN : Showcases Oncology Pipeline At ASCO 2020
05/12AMGEN : To Present At The Bank Of America Merrill Lynch Virtual Global Healthcar..
05/12Lundbeck boosted by stockpiling, launches key drug remotely
More news
Financials (USD)
Sales 2020 25 316 M
EBIT 2020 11 986 M
Net income 2020 7 302 M
Debt 2020 23 293 M
Yield 2020 2,77%
P/E ratio 2020 18,0x
P/E ratio 2021 15,9x
EV / Sales2020 6,18x
EV / Sales2021 5,83x
Capitalization 133 B
Duration : Period :
Amgen Inc. Technical Analysis Chart | AMGN | US0311621009 | MarketScreener
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 251,44 $
Last Close Price 226,43 $
Spread / Highest target 28,5%
Spread / Average Target 11,0%
Spread / Lowest Target -18,3%
EPS Revisions
Robert A. Bradway Chairman, President & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
Peter H. Griffith Chief Financial Officer
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN INC.-6.07%133 197
JOHNSON & JOHNSON-1.03%380 356
ROCHE HOLDING AG10.48%303 907
PFIZER, INC.-4.29%208 306
MERCK & CO., INC.-16.03%192 766
NOVARTIS AG-10.58%186 299